I've contacted them about this trial because I have a TET2 mutation but they're currently amending the trial so enrollment is not open. However, they encouraged me to send them my records so if I'm accepted they could hit the ground running to get me in the trial once they're open again.
---------------------------------------------------
MDSF Center of Excellence, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, is conducting a study on high dose vitamin C and its effect on the TET2 mutation in patients with MDS.
Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers.
You may be eligible for this study if you meet the following criteria:
Conditions:
• Myelodysplastic Syndrome with positive TET2 mutations
• Between 18 - 99 Years
• Male or Female
• Myeloblasts account for less than 20% of leukocytes
• Adequate organ function
If you are interested, please contact the MDSF or the Center of Excellence directly (Dr. Raoul Tibes via email at
Raoul.Tibes@nyulangone.org).